Skip to main content

Tafamidis Disease Interactions

There are 2 disease interactions with tafamidis.

Moderate

Tafamidis (applies to tafamidis) hypothyroidism

Moderate Potential Hazard, Moderate plausibility.

Tafamidis binds to transthyretin (TTR) at the thyroxine binding sites. The use of tafamidis may decrease serum concentrations of total thyroxine, without an accompanying change in thyroid stimulating hormone (TSH). The reduction in total thyroxine values is probably the result of reduced thyroxine binding to or displacement from transthyretin due to the high binding affinity of tafamidis to the TTR thyroxine receptor. No corresponding clinical findings consistent with hypothyroidism have been observed. Exercise care when using this agent in patients with hypothyroidism.

References

  1. "Product Information. Vyndaqel (tafamidis)." Pfizer U.S. Pharmaceuticals Group (2019):
Moderate

Tafamidis (applies to tafamidis) liver disease

Moderate Potential Hazard, Moderate plausibility.

The use of tafamidis in patients with moderate hepatic impairment (Child-Pugh Score of 7 to 9) demonstrated decreased systemic exposure (approximately 40%) and increased clearance (approximately 68%) when compared to healthy subjects. No clinically significant differences in the pharmacokinetics of tafamidis were observed in patients with mild hepatic impairment (Child Pugh Score of 5 to 6). Use caution when using this agent in patients with severe hepatic impairment as its effect is unknown.

References

  1. "Product Information. Vyndaqel (tafamidis)." Pfizer U.S. Pharmaceuticals Group (2019):

Tafamidis drug interactions

There are 30 drug interactions with tafamidis.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer